Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 6,354 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intestinal Disorders Clear all
Completed Phase 2 Interventional Results available

A Placebo-Controlled Trial of St. John's Wort for Irritable Bowel Syndrome

NCT00587860
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
St. John's wort, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Not applicable Interventional

Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease

NCT04147585
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Diet Modification
Interventions
Intermittent Reduced Calorie Diet (IRCD)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

NCT03806127
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 20, 2026, 3:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

NCT06620627
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
40 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Not applicable Interventional

Dietary Intervention and Gastrointestinal Function in Patients With Parkinson's Disease

NCT03851861
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mediterranean Diet
Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 20, 2026, 3:51 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

NCT04963283
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer, Rectal Cancer, Rectal Adenocarcinoma, Colorectal Cancer
Interventions
Cabozantinib, Nivolumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Terminated Not applicable Interventional

Effect of Acupuncture on Symptoms of Diarrhea and Pain in IBS

NCT00219505
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
acupuncture
Procedure
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 20, 2026, 3:51 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families

NCT07542405
View directory record Official record
Conditions
BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome, BRCA2-Related Hereditary Breast and Ovarian Cancer Syndrome, Hereditary Neoplastic Syndrome, Lynch Syndrome
Interventions
Discussion, Internet-Based Intervention, Survey Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Recruiting Not applicable Interventional

An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer

NCT05914766
View directory record Official record
Conditions
Rectal Cancer, Self Efficacy
Interventions
PATHWAYS, Enhanced usual care
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Not applicable Interventional Results available

Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer

NCT01226979
View directory record Official record
Conditions
Rectal Cancer
Interventions
High-dose endorectal brachytherapy (HDRBT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 20, 2026, 3:51 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04677179
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Litchfield Park, Arizona • Kissimmee, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 20, 2026, 3:51 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Phase I Biomarker Study of Dietary Grape-derived Low Dose Resveratrol for Colon Cancer Prevention

NCT00578396
View directory record Official record
Conditions
Colon Cancer
Interventions
grapes
Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 20, 2026, 3:51 PM EDT
Active, not recruiting No phase listed Observational

Emulation of the MAVERICC Trial Using Specialty Oncology Electronic Health Records Databases

NCT07861386
View directory record Official record
Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
FOLFIRI plus bevacizumab, mFOLFOX6 plus bevacizumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
9,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Withdrawn Not applicable Interventional

Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy

NCT01941173
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
ziv-aflibercept, leucovorin calcium, irinotecan hydrochloride, fluorouracil
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
3
States / cities
Duarte, California • Lancaster, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

NCT00416351
View directory record Official record
Conditions
Leukemia, Lymphoma, Small Intestine Cancer
Interventions
clofarabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
3
States / cities
New York, New York • Rochester, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer

NCT00114231
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
67
States / cities
Scottsdale, Arizona • Concord, California • Duarte, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 20, 2026, 3:51 PM EDT
Completed No phase listed Observational

Patients' Preferences About Rescheduling Colonoscopies Delayed Due to COVID-19: Cross Sectional Study

NCT04432870
View directory record Official record
Conditions
Colon Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 75 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 20, 2026, 3:51 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

NCT03182894
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)
Drug
Lead sponsor
James J Lee
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 20, 2026, 3:51 PM EDT
Terminated No phase listed Observational

Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00536523
View directory record Official record
Conditions
Constipation, Bowel Obstruction, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Not applicable Interventional

Sex Differences in Effectiveness of CBT on IBS Project 3

NCT05155631
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
COGNITIVE BEHAVIORAL THERAPY
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 2 Interventional

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

NCT02576431
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
BAY2757556 (Larotrectinib, Vitrakvi)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Not yet recruiting Not applicable Interventional

Isocaloric Navy-Bean Substitution in Adults With MASLD

NCT07730853
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control)
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

NCT07063823
View directory record Official record
Conditions
Celiac Disease, Healthy
Interventions
HB-2121
Drug
Lead sponsor
Nielsen Fernandez-Becker
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 3:51 PM EDT
Completed Phase 3 Interventional Results available

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

NCT00561470
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasm Metastasis
Interventions
Placebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
87
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 20, 2026, 3:51 PM EDT